Nov Stock

Nov EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Nov (NOV) as of Aug 13, 2026 is 12.00. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 7.73 — a change of 55.32% (higher).

EV/EBIT

12.00

YoY

55.32%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Nov is 2026 12.00 . EV/EBIT (Enterprise Value to EBIT) of Nov was 2025 7.73 . It decreases by 55.32% higher compared to the previous year.

The Nov EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-1.50 base
Jan 1, 2020
-1.96 base
Jan 1, 2021
-32.37 base
Jan 1, 2022
31.26 base
Jan 1, 2023
12.37 base
Jan 1, 2024
6.50 base
Jan 1, 2025
10.17 base
Jan 1, 2026 (e)
5.63 base
YEARPRICE-TO-EBIT
2026 est 5.63
2025 10.17
2024 6.50
2023 12.37
2022 31.26
2021 -32.37
2020 -1.96
2019 -1.50
2018 73.46
2017 -43.11
2016 -5.59
2015 -32.20
2014 7.76
2013 9.62
2012 7.78
2011 8.83
2010 10.41
2009 7.16
2008 3.14
2007 11.54
2006 8.73
Access this data via the Eulerpool API

Nov Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Nov's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Nov's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Nov's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Nov grows earnings faster than its peers.

Nov Stock analysis

What does Nov do? Nov Inc is a globally operating company that was founded in the USA in 1976. The company specializes in the development and manufacture of products in various fields, including pharmaceuticals, biotechnology, agrochemicals, and electronics. Nov Inc's business model is based on the research and development of new technologies and products. The company invests a significant portion of its resources in the research and development of new drugs and technologies. Nov Inc works closely with scientific organizations and universities to achieve this. The goal of Nov Inc is to develop products that have a positive impact on health, science, and the environment. The company aims to improve the quality of life for people worldwide by developing innovative products that meet the needs of its customers. Nov Inc is divided into several divisions. The main divisions are pharmaceuticals, biotechnology, diagnostics, crop protection, and electronics. In each of these divisions, the company produces products tailored to the needs of its customers. In the pharmaceutical field, Nov Inc develops and produces drugs for the treatment of various diseases such as cancer, diabetes, and cardiovascular diseases. Nov Inc's products are well-known worldwide and are taken by millions of patients every day. The company is proud to make a significant contribution to improving the health of people worldwide. In the biotechnology division, Nov Inc develops products for use in agriculture and environmental protection. This includes improved seed varieties that are more resistant to insects and diseases, thus reducing the use of pesticides. Nov Inc also produces biological pesticides that protect plants from pests while being non-toxic and environmentally friendly. In the diagnostics division, Nov Inc develops and produces tests for the diagnosis of infectious diseases and other medical conditions. These tests are important for the timely detection of diseases and enable early treatment. In the electronics division, Nov Inc develops and produces electronic devices and components. This includes semiconductors, sensors, and displays. These components are used in various industries, including telecommunications, automotive, and aerospace. In addition to the above-mentioned divisions, Nov Inc also offers other products, including food additives, colorants, fragrances, and chemicals for industrial use. Overall, Nov Inc has made a significant contribution to improving health, science, and the environment over the past decades. The company is globally recognized for its innovative products and technologies and will remain an important player in research and development in the future. Nov is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nov stock

EV/EBIT (Enterprise Value to EBIT) of Nov is 12.00 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Nov changed from 7.73 to 12.00, representing a 55.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Nov since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Nov with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Nov

All Key Metrics — Nov